The study, published in the journal Biological Psychiatry, showed that SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants have the potential to improve certain cognitive functions, such as verbal memory. ​

Chest pain is a common but challenging symptom for general practitioners to evaluate, as it can be caused by both serious conditions and more benign issues.

The degree to which a surgical patient's subconscious processing of pain, or "nociception," is properly managed by their anesthesiologist will directly affect the degree of post-operative drug side effects they'll experience and the need for further pain management they'll require.

A significant breakthrough in the understanding of sleep mechanism opens new promise for treating sleep disorders and associated neuropsychiatric conditions: Scientists have pinpointed the melatonin receptor MT1 as a crucial regulator of REM (Rapid Eye Movement) sleep.

Researchers have found a substance that effectively combats glioblastomas, at least in the laboratory: an antidepressant called vortioxetine.

Josh Leonardis received funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health to study why female manual wheelchair users experience shoulder pain and pathology at greater rates than males.

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

This study identifies serum miRNA signatures as promising biomarkers for Alzheimer's, enhancing prediction of MCI conversion to AD with clinical relevance.

Researchers have found that SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants have the potential to improve certain cognitive functions, such as verbal memory. They measured brain function in patients before and after taking the SSRI escitalopram and correlated this to a drop in the level of one of the serotonin receptors in the brain and to cognitive improvements during treatment.

The study, published in BMC Medicine, provides “scientifically controlled evidence that a single guided digital treatment session can reduce the number of intrusive memories”. ​

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for all patients with cancers caused by KRAS mutations.